Comparing two prostate biopsy methods for finding prostate cancer
Compares biopsy near the MRI-visible spot with whole-prostate sampling in men suspected of prostate cancer.
Plain-language title generated from the registry record
Registry title: Targeted And Perilesional Or Systematic Biopsy In Prostate Cancer
Key facts
- Where
- Bordeaux, Marseille, Mont-de-Marsan, Paris, and Quint-Fonsegrives, FranceSee the 5 sites
Where in France
- CHU de BordeauxBordeaux, FranceNo longer taking part
- Hôpital Nord, Assistance Publique des Hôpitaux de MarseilleMarseille, FranceNo longer taking part
- CHI Mont de Marsan - Site de LaynéMont-de-Marsan, FranceNo longer taking part
- Hôpital privé des Peupliers - Ramsay SantéParis, FranceNo longer taking part
- Clinique La Croix du Sud - Ramsay SanteQuint-Fonsegrives, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GCS Ramsay Santé pour l'Enseignement et la Recherche
- Trial code
- NCT07296042
- Record updated
- 15 September 2026
- Original description
Magnetic Resonance Imaging (MRI) improves the detection of clinically significant prostate cancer (PCa) by guiding biopsies of MRI-visible lesions (targeted biopsies) in patients suspected with having PCa. This strategy increases the detection of clinically significant PCa, however, while also increasing the detection of insignificant prostate cancer, often synonymous of "overdiagnosis".Read full original descriptionShow less
Targeted And Perilesional Or Systematic Biopsy In Prostate Cancer
Magnetic Resonance Imaging (MRI) improves the detection of clinically significant prostate cancer (PCa) by guiding biopsies of MRI-visible lesions (targeted biopsies) in patients suspected with having PCa. This strategy increases the detection of clinically significant PCa, however, while also increasing the detection of insignificant prostate cancer, often synonymous of "overdiagnosis".
It is well known that insignificant PCa has a very low risk of local and distant progression, and active surveillance with a deferred curative treatment protocol based on clear indicators of disease progression is now recommended for all insignificant PCa. However, higher detection of insignificant PCa can lead to patient anxiety about inclusion in an active surveillance protocol, potential further damage from repeated surveillance biopsies and higher healthcare costs.
Thus, there is a need for a new biopsy scheme that maintains clinically significant PCa's detection while reducing the diagnosis of insignificant PCa. In recent years, an alternative approach has been to add additional cores close to the target lesion, this is defined as regional biopsies. The hypothesis is that most clinically significant PCa missed in the target are found close to the target. Whereas most cancers found on systematic biopsies outside the MRI target probably correspond to insignificant PCa. This strategy aims to maintain the detection of clinically significant PCa, while reducing the detection of insignificant PCa.
This proposed multicenter diagnostic study aims to demonstrate the effectiveness of the experimental biopsy scheme (targeted + regional) in detecting clinically significant PCa, compared with a conventional scheme (targeted + systematic). We also aim to compare the detection of insignificant PCa by both schemes.
Inclusion: Adult men (≥ 18 years old); Clinical suspicion of PCa (based on digital rectal examination, family history, PSA and PSA density values) and prescribed prostate biopsy; Detection by multi-parametric MRI of the prostate of a PI-RADS 4 or 5 index lesion, or a PI-RADS 3 index lesion with a PSA density ≥ 0.15 ng/ml/cc; Patient eligible for prostate biopsy under local or general anesthesia; PSA ≤ 20 ng/mL; Patient who agreed to participate in the study and signed the consent form.
Exclusion: History of prostate cancer; History of negative prostate biopsy; Patient unable to understand the terms of the study or unable to give informed consent (neurological or psychiatric disorders, non-French speaker, etc.); MRI negative (PI-RADS 1 or 2) or equivocal (PI-RADS 3) with PSA density < 0.15 ng/ml/cc; Patient under full or partial legal guardianship.